S Staszewski

Summary

Affiliation: Zentrum der Inneren Medizin
Country: Germany

Publications

  1. ncbi ["State of the HAART". Current strategies for antiretroviral therapy]
    S Staszewski
    Schwerpunkt HIV am Zentrum der Inneren Medizin, Klinik II, Klinikum der Johann Wolfgang Goethe Unversität Frankfurt
    Internist (Berl) 45:1428-36. 2004
  2. ncbi Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
    S Staszewski
    Klinikum der Johann Wolfgang Goethe Universitat, Zentrum der Inneren Medizin, Infektionsambulanz, Haus 68, Theodor Stern Kai 7, D 60596 Frankfurt, Germany
    JAMA 285:1155-63. 2001
  3. ncbi Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure
    V Miller
    Zentrum der Inneren Medizin, Klinikum der J W Goethe Universitat, Frankfurt, Germany
    J Infect Dis 177:1521-32. 1998
  4. ncbi CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load
    V Miller
    Zentrum der Inneren Medizin, J W Goethe Universitat, 60590 Frankfurt, Germany
    J Infect Dis 180:530-3. 1999
  5. ncbi HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort
    V Miller
    Klinikum der JW Goethe Universität, Zentrum der Inneren Medizin, Frankfurt, Germany
    Antivir Ther 5:49-55. 2000
  6. ncbi Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users
    S Staszewski
    Klinikum der JW Goethe Universität Frankfurt, Zentrum der Inneren Medizin, Germany
    Antivir Ther 3:55-6. 1998
  7. ncbi Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R
    C Stephan
    HIVCENTER, Johann Wolfgang Goethe University Hospital, Department of Internal Medicine II, Theodor Stern Kai 7, Frankfurt, Germany
    J Infect 61:346-50. 2010
  8. ncbi The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load
    V Miller
    Klinikum der JohannWolfgang Goethe Universität, Zentrum der Inneren Medizin, Frankfurt, Germany
    AIDS 14:2129-36. 2000
  9. ncbi Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride
    V Miller
    Zentrum der Inneren Medizin, J W Goethe Universitat, Frankfurt, Germany
    Antimicrob Agents Chemother 42:3123-9. 1998
  10. ncbi Switch to efavirenz (EFV) after protease-inhibitor (PI)-failure: explorative analysis of outcome by baseline viral VS tolerability failure
    Pavel Khaykin
    HIVCENTER, HIV Treatment and Clinical Research Unit, Department of Internal Medicine II, Johann Wolfgang Goethe University, Theodor Stern Kai 7, Haus 68, 60590, Frankfurt am Main, Germany
    Eur J Med Res 13:169-72. 2008

Detail Information

Publications31

  1. ncbi ["State of the HAART". Current strategies for antiretroviral therapy]
    S Staszewski
    Schwerpunkt HIV am Zentrum der Inneren Medizin, Klinik II, Klinikum der Johann Wolfgang Goethe Unversität Frankfurt
    Internist (Berl) 45:1428-36. 2004
    ..Phase 3:replication of resistant HIV (no more mutations possible).a)stable immunity: continue with failing therapy.b)threatening disease progression: resistance-guided switch to a salvage-regimen...
  2. ncbi Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
    S Staszewski
    Klinikum der Johann Wolfgang Goethe Universitat, Zentrum der Inneren Medizin, Infektionsambulanz, Haus 68, Theodor Stern Kai 7, D 60596 Frankfurt, Germany
    JAMA 285:1155-63. 2001
    ..However, the role of abacavir in a triple nucleoside combination regimen has not been evaluated against a standard protease inhibitor-containing regimen for initial antiretroviral treatment...
  3. ncbi Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure
    V Miller
    Zentrum der Inneren Medizin, Klinikum der J W Goethe Universitat, Frankfurt, Germany
    J Infect Dis 177:1521-32. 1998
    ..After adjustment for all variables, phenotypic resistance to zidovudine remained the only significantly associated factor, independent of baseline CD4+ cell count, baseline CDC classification, and virus load...
  4. ncbi CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load
    V Miller
    Zentrum der Inneren Medizin, J W Goethe Universitat, 60590 Frankfurt, Germany
    J Infect Dis 180:530-3. 1999
    ....
  5. ncbi HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort
    V Miller
    Klinikum der JW Goethe Universität, Zentrum der Inneren Medizin, Frankfurt, Germany
    Antivir Ther 5:49-55. 2000
    ..To assess the relationship between viral susceptibility at baseline and virological response in human immunodeficiency virus (HIV)-infected patients treated with multi-drug salvage regimens after multiple previous treatment failures...
  6. ncbi Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users
    S Staszewski
    Klinikum der JW Goethe Universität Frankfurt, Zentrum der Inneren Medizin, Germany
    Antivir Ther 3:55-6. 1998
    ..Preliminary results for the first 24 weeks show that the regimen provides potent immunological and antiviral effects...
  7. ncbi Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R
    C Stephan
    HIVCENTER, Johann Wolfgang Goethe University Hospital, Department of Internal Medicine II, Theodor Stern Kai 7, Frankfurt, Germany
    J Infect 61:346-50. 2010
    ..The reverse transcriptase (RT)-mutation K65R limits further therapeutic options and has been selected by unfavorable RT-combinations, e.g. tenofovir in combination with abacavir and/or didanosine...
  8. ncbi The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load
    V Miller
    Klinikum der JohannWolfgang Goethe Universität, Zentrum der Inneren Medizin, Frankfurt, Germany
    AIDS 14:2129-36. 2000
    ..To compare the rate of disease progression according to viral load and CD4 cell count in patients receiving or not receiving highly active antiretroviral therapy (HAART), defined as protease inhibitor-containing regimens...
  9. ncbi Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride
    V Miller
    Zentrum der Inneren Medizin, J W Goethe Universitat, Frankfurt, Germany
    Antimicrob Agents Chemother 42:3123-9. 1998
    ..Our data indicate that the available newer NNRTIs which retain activity against some HIV-1 strains selected by other compounds of this class in vitro may have compromised clinical efficacy in some patients pretreated with NNRTI...
  10. ncbi Switch to efavirenz (EFV) after protease-inhibitor (PI)-failure: explorative analysis of outcome by baseline viral VS tolerability failure
    Pavel Khaykin
    HIVCENTER, HIV Treatment and Clinical Research Unit, Department of Internal Medicine II, Johann Wolfgang Goethe University, Theodor Stern Kai 7, Haus 68, 60590, Frankfurt am Main, Germany
    Eur J Med Res 13:169-72. 2008
    ....
  11. ncbi Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults
    Nils von Hentig
    Institute for Clinical Pharmacology, J W Goethe University Hospital, Frankfurt, Theodor Stern Kai 7, D 60590 Frankfurt M, Germany
    Eur J Med Res 11:236-44. 2006
    ..The authors evaluated the pharmacokinetics and tolerability of indinavir/lopinavir/ritonavir in a protease inhibitor only combination...
  12. ncbi Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study
    V Rickerts
    Klinikum der J W Goethe Universität Frankfurt, Med Klinik III Infektiologie, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Eur J Med Res 5:329-33. 2000
    ..To investigate whether the use of highly active antiretroviral therapy (HAART) is associated with an increased incidence of myocardial infarctions (MI) in HIV infected patients...
  13. ncbi Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
    W M El-Sadr
    Ann Intern Med 149:289-99. 2008
    ..Episodic antiretroviral therapy, as used in the SMART study, should be avoided...
  14. ncbi Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
    ..In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART...
  15. ncbi Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
    ..Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported...
  16. ncbi Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals
    A N Phillips
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 15:2379-84. 2001
    ..The major challenge is to develop regimens that can be taken consistently and safely for such long periods of time...
  17. ncbi Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies
    G Chene
    Department of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH 3012, Bern, Switzerland
    Lancet 362:679-86. 2003
    ..We examined whether the initial virological and immunological response to highly active antiretroviral treatment (HAART) is prognostic in patients with HIV-1 who start HAART...
  18. ncbi Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group
    A Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College London Medical Schools, London, United Kingdom
    J Infect Dis 190:1947-56. 2004
    ....
  19. ncbi Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 48:324-33. 2008
    ..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy...
  20. ncbi Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction
    C A Sabin
    Dept of Primary Care and Population Sciences, Royal Free and UC Medical School, Rowland Hill St, London, NW3 2PF, United Kingdom
    Clin Infect Dis 46:1101-10. 2008
    ..We evaluated changes in risk factors for CVD and the use of lipid-lowering therapy in HIV-infected individuals and assessed the impact of any changes on the incidence of myocardial infarction...
  21. ncbi Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
    Caroline A Sabin
    Lancet 371:1417-26. 2008
    ..The excess risk does not seem to be explained by underlying established cardiovascular risk factors and was not present beyond 6 months after drug cessation...
  22. ncbi Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men
    Alexander Kreuter
    1Department of Dermatology, Ruhr University Bochum, Bochum, Germany
    J Invest Dermatol 128:2078-83. 2008
    ..However, new AIN lesions associated with previously undetected HPV types frequently occur in untreated areas...
  23. ncbi Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy
    A Calmy
    St Vincent s Hospital, Sydney, Australia
    HIV Med 9:101-10. 2008
    ..We investigated whether metabolic and body composition parameters could predict the development of LD over 2 years in adults initiating antiretroviral therapy (ART)...
  24. ncbi A standardized, comprehensive magnetic resonance imaging protocol for rapid and precise quantification of HIV-1-associated lipodystrophy
    M Bickel
    HIV Medical Treatment and Research Unit, JW Goethe University, Frankfurt, Germany
    HIV Med 8:413-9. 2007
    ..Although multiple methods have been proposed, there is no current gold standard for assessing HIV-1-associated lipodystrophy...
  25. ncbi First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe aplastic anemia
    T Wolf
    Department of Infectious Diseases, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
    Haematologica 92:e56-8. 2007
    ..The patient is in good condition with an ECOG score of 0 twelve months after transplantation. This report demonstrates the feasibility of allogeneic stem cell transplantation in the HIV setting...
  26. ncbi Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients
    B Salzberger
    Klinik I fuer Innere Medizin, Universitaetsklinik Regensburg, 93042 Regensburg, Germany
    Eur J Med Res 12:93-102. 2007
    ..The IAS concluded that the likelihood of achieving this treatment goal is higher when enfuvirtide is selected as one of the two active drugs...
  27. ncbi Dose reduction effective in alleviating symptoms of saquinavir toxicity
    C Stephan
    Medical HIV Treatment and Research Unit, Hospital of the Johann Wolfgang Goethe University, Department of Internal Medicine II, Frankfurt, Germany
    Int J STD AIDS 18:81-4. 2007
    ..Although delayed autoinduction is not well established as a reason for adverse events in saquinavir therapy, this observation may be confirmed in the near future by increased use...
  28. ncbi Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis
    M W Lorenz
    Johann Wolfgang Goethe University Hospital, Department of Neurology, Frankfurt am Main, Germany
    Atherosclerosis 196:720-6. 2008
    ..We investigated the relationship between HIV infection, antiretroviral medication and ultrasound evidence of early atherosclerosis in the context of vascular risk factors...
  29. ncbi The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era
    A Mocroft
    Royal Free Centre for HIV Medicine, Dept Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill St, London NW3 2PF, UK
    Clin Trials 3:119-32. 2006
    ..Cohort studies of patients with HIV can provide key estimates of the likely disease progression, required sample size and follow-up...
  30. ncbi Updated European recommendations for the clinical use of HIV drug resistance testing
    A M Vandamme
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
    Antivir Ther 9:829-48. 2004
    ..The panel also encourages the timely collection of epidemiological information to estimate the impact of transmission of resistant HIV and the prevalence of HIV-1 non-B subtypes in the different European countries...
  31. ncbi A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy
    M Bickel
    HIV Treatment and Research Unit, JW Goethe University, Frankfurt, Germany
    HIV Med 7:397-403. 2006
    ..Several studies have shown beneficial effects of recombinant human growth hormone (r-hGH) in reducing visceral adipose tissue (VAT) in HIV-1-infected patients with lipodystrophy...